Delhi, July 21, 2022 (GLOBE NEWSWIRE) — Technological advancements including gene sequencing and target gene selection have led to introduction of targeted therapies in the management of cancer. Amid all therapies, antibody therapeutics have emerged as shining star in the global market owing to their ability to specifically target the disease and generating specific immune response against it. Despite huge success, there is still a room for more enhanced therapeutics which has propelled the further research and development activities. Scientists are continuously identifying new potential targets for the designing of enhanced drug.
Better understanding in the cancer biology has led to identification of next generation immune checkpoint inhibitor, T-cell immunoglobulin mucin-3 (TIM-3). The expression of TIM-3 has been reported on interferon (IFN) gamma (γ) secreting helper T (Th) 1 cells, Th17, regulatory T cells (Tregs), CD8+ T cells, dendritic cells, monocytes, and other leukocyte subsets, including natural killer (NK) cells. Several studies evidence also suggests that TIM-3 is expressed on cancer cells such as melanoma, osteosarcoma, cervical cancer, renal cell carcinoma, and others. The ubiquitous expression of TIM-3 on multiple tumor cells strongly indicates its potential role in tumor progression.
Current research studies are mainly focused on exploring the beneficial effects of blocking or modulating TIM-3 as therapy for cancer. Owing to its…
